EQS-News: SHOP APOTHEKE EUROPE N.V. PUBLISHES CONVOCATION FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS 2023
EQS-News: SHOP APOTHEKE EUROPE N.V.
/ Key word(s): AGM/EGM
SHOP APOTHEKE EUROPE N.V. PUBLISHES CONVOCATION FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS 2023
15.03.2023 / 18:34 CET/CEST
The issuer is solely responsible for the content of this announcement.
NOT FOR DIRECT OR INDIRECT RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, CANADA, SOUTH AFRICA, AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE N.V. PUBLISHES CONVOCATION FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS 2023
Sevenum, 15 March 2023. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE EUROPE" or the "Company") has today published the convocation for the annual general meeting of shareholders of the Company to be held on 26 April 2023 (the "AGM").
The AGM materials (including the convocation notice, the agenda with the explanatory notes thereto as well as other relevant documentation) are available on the corporate website of the Company (http://shop-apotheke-europe.com) under Investor Relations / General Meeting / Annual General Meeting 2023 and via the link: http://shop-apotheke-europe.com/en/investorrelations/hauptversammlung/
Among other things, shareholders at this year's AGM will vote on the Company's name change, the appointment of a new CEO and the 2022 Annual Report.
The AGM is scheduled to take place on 26 April 2023 starting at 10:00 CEST, and will take place as a hybrid meeting, meaning that shareholders are given the option to either participate in the AGM (i) in person at the Company's headquarters, Erik de Rodeweg 11-13, Sevenum, the Netherlands or (ii) virtually, through the online platform provided by the Company’s service provider Better Orange IR & HV AG (such platform the "Online Platform").
Taking into consideration that the Covid-19 virus may still pose a health risk for shareholders and employees of the Company, the Company strongly encourages its shareholders to take part in the AGM via the Online Platform and not to attend the AGM in person.
For further information please contact us at:
General AGM related matters:
Rens Jan Kramer
Telephone: +31 6 46 18 67 23
Email: [email protected]
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: [email protected]
15.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
SHOP APOTHEKE EUROPE N.V. |
|
Erik de Rodeweg 11-13 |
|
5975 WD Sevenum |
|
Netherlands |
Phone: |
0800 - 200 800 300 |
Fax: |
0800 - 90 70 90 20 |
E-mail: |
[email protected] |
Internet: |
www.shop-apotheke-europe.com |
ISIN: |
NL0012044747, DE000A19Y072 |
WKN: |
A2AR94, A19Y07 |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1583661 |
|
End of News |
EQS News Service |
1583661 15.03.2023 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
283,99 |
539,71 |
701,01 |
968,06 |
1.060,32 |
1.204,35 |
1.798,76 |
EBITDA1,2 |
-12,14 |
-15,56 |
-18,58 |
15,20 |
-38,73 |
-29,66 |
39,99 |
EBITDA-Marge3 |
-4,27 |
-2,88 |
-2,65 |
1,57 |
-3,65 |
-2,46 |
|
EBIT1,4 |
-19,20 |
-28,73 |
-33,45 |
-0,87 |
-65,70 |
-69,17 |
-17,30 |
EBIT-Marge5 |
-6,76 |
-5,32 |
-4,77 |
-0,09 |
-6,20 |
-5,74 |
-0,96 |
Jahresüberschuss1 |
-21,36 |
-33,61 |
-36,27 |
-16,77 |
-74,19 |
-77,65 |
-11,61 |
Netto-Marge6 |
-7,52 |
-6,23 |
-5,17 |
-1,73 |
-7,00 |
-6,45 |
-0,65 |
Cashflow1,7 |
-23,24 |
-23,54 |
-30,37 |
17,80 |
11,64 |
-29,11 |
61,46 |
Ergebnis je Aktie8 |
-2,25 |
-2,79 |
-2,78 |
-1,17 |
-4,15 |
-4,32 |
-0,73 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Mazars
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Redcare Pharmacy |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2AR94 |
130,000 |
Halten |
2.644,52 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
72,22 |
0,00 |
0,00 |
-62,26 |
KBV |
KCV |
KUV |
EV/EBITDA |
5,06 |
43,03 |
1,47 |
70,23 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
17.04.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
25.04.2024 |
30.07.2024 |
05.11.2024 |
05.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-6,61% |
6,18% |
-0,76% |
39,82% |
|
|